o

EUROPEAN MEDICINES AGENCY

SCIENCE MEDICINES HEALTH

EMA/310857/2016

EMEA/H/C/003999

EPAR summary for the public

EndolucinBeta

lutetium (¹⁷⁷Lu) chloride

This is a summary of the European public assessment report (EPAR) for EndolucinBeta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.

It is not intended to provide practical advice on how to use EndolucinBeta.

For practical information about using EndolucinBeta, patients should read the package leaflet or contact their doctor or pharmacist.

What is EndolucinBeta and what is it used for?

EndolucinBeta contains the radioactive compound lutetium (¹⁷⁷Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example the site of a tumour.

EndolucinBeta is only to be used to radiolabel medicines that have been specifically developed for use with EndolucinBeta.

How is EndolucinBeta used?

EndolucinBeta is only used by specialists who have experience in radiolabelling.

EndolucinBeta is never given to a patient on its own. Radiolabelling with EndolucinBeta takes place in a laboratory. The radiolabelled medicine is then given to the patient according to the instructions in that medicine's product information.

How does EndolucinBeta work?

The active substance in EndolucinBeta, lutetium (¹⁷⁷Lu) chloride, is a radioactive compound that mainly emits a type of radiation known as beta radiation, with small amounts of gamma radiation.

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

When a medicine radiolabelled with EndolucinBeta is given, it carries the radiation to where it is needed in the body, either to kill cancer cells (when used for treatment) or to obtain images on a screen (when used in diagnosis).

What benefits of EndolucinBeta have been shown in studies?

Several published studies have established the usefulness of lutetium (¹⁷⁷Lu) in radiolabelling medicines for diagnosing and treating neuroendocrine tumours. This is a group of tumours that affect hormone-secreting cells in many parts of the body, including the pancreas, intestine, stomach and lungs. The benefits of EndolucinBeta will largely depend on the medicine that it is used to radiolabel.

What are the risks associated with EndolucinBeta?

The side effects with EndolucinBeta depend largely on the medicine it is used with and will be described in that medicine's package leaflet. EndolucinBeta itself is radioactive, and as with any other radioactive product, its use may carry a risk of developing cancer and defects that are passed on to children. However, the quantity of EndolucinBeta to be used is very small and therefore these risks are considered low. The doctor will ensure that the expected benefit to the patients of using EndolucinBeta outweigh the risks linked to the radioactivity.

Medicines radiolabelled with EndolucinBeta must not be used in pregnant women or women who may be pregnant. For the full list of all restrictions on the use of EndolucinBeta, see the package leaflet. Information on restrictions that apply specifically to medicines radiolabelled with EndolucinBeta can be found in the package leaflets of those medicines.

Why is EndolucinBeta approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that the use of lutetium (¹⁷⁷Lu) for radiolabelling medicines was well documented in the scientific literature. As with all radiolabelling materials for medicines, there are risks linked to radiation exposure from EndolucinBeta. Information on how to minimise the risks is included in the product information for EndolucinBeta.

The CHMP concluded that the benefits of EndolucinBeta outweigh the risks and recommended that it be given marketing authorisation.

What measures are being taken to ensure the safe and effective use of EndolucinBeta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of EndolucinBeta have been included in the summary of product characteristics and the package leaflet.

Other information about EndolucinBeta

The European Commission granted a marketing authorisation valid throughout the European Union for EndolucinBeta on 06 July 2016.

The full EPAR for EndolucinBeta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. For more information about treatment with EndolucinBeta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 07-2016.

EndolucinBeta

EMA/310857/2016    Page 2/2